Caxton Associates LP Alaunos Therapeutics, Inc. Transaction History

Caxton Associates LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.46 - $0.81 $11,816 - $20,806	-25,687 Reduced 8.23%	286,287 $180,000
Q3 2022 Nov 14, 2022	BUY	$1.04 - $322.5 $219,709 - $68.1 Million	211,259 Added 209.76%	311,974 $537,000
Q2 2022 Aug 15, 2022	SELL	$0.41 - $1.24 $16,620 - $50,268	-40,539 Reduced 28.7%	100,715 $125,000
Q4 2021 Feb 14, 2022	BUY	$1.09 - $1.89 $153,966 - $266,970	141,254 New	141,254 $154,000
Q1 2020 May 15, 2020	SELL	$1.9 - $4.98 $52,261 - $136,979	-27,506 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.95 - $5.35 $108,648 - $147,157	27,506 New	27,506 $130,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.